Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Leighton Welch’s Welch Capital Partners Is Betting On These Stocks

Page 1 of 2

Leighton Welch’s Welch Capital Partners has filed its 13F with the U.S. Securities and Exchange Commission for the reporting period of June 30, 2015. The hedge fund has a long/short investment approach based upon fundamental valuation of a given stock. According to its website, the investment advisory firm targets companies with the highest relative growth rates, new product cycles, and practical commercialization strategies, for long-term investing. On the contrary, its short investing focuses on companies with slowing growth rates, overvalued shares, and stocks with pending catalysts for decline. According to its 13F filing, the hedge fund has a public equity portfolio worth $335.56 million, with its primary investments being in the finance, healthcare, and information technology sectors. We decided to take a closer look at the largest equity investments of Leighton Welch and identify the prevailing hedge fund sentiment around these stocks. Zimmer Biomet Holdings Inc (NYSE:ZBH), Grupo Televisa SAB (ADR) (NYSE:TV), Oracle Corporation (NYSE:ORCL) are the top three stocks in Welch Capital’s portfolio, which we’ll discuss below.

Oracle ORCL

But first, we don’t just track the latest moves of funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 2.5 years. The results of our analysis show that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests. Moreover, since the beginning of forward testing in August 2012, the strategy worked brilliantly, outperforming the market every year and returning 123%, which is more than 65 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

Leighton Welch
Leighton Welch
Welch Capital Partners

Zimmer Biomet Holdings Inc (NYSE:ZBH) comes in at the top of the equity investments of Leighton Welch. The investor’s hedge fund reported ownership of 183,158 shares of the healthcare company, with market value of $20.01 million. Zimmer Biomet Holdings Inc (NYSE:ZBH) reported better-than-expected second quarter 2015 financial results, surpassing Wall Street’s earnings expectations of $1.56 with reported EPS of $1.59. It was an excellent quarter for the newly-combined company, although the quarterly revenue of $1.17 billion fell short of the market’s expectations of $1.19 billion. Zimmer Holdings, Inc. (NYSE:ZMH) completed the acquisition of Biomet in June for $14 billion in a cash and equity transaction. The company changed its name to Zimmer Biomet Holdings Inc (NYSE:ZBH) after the merger and the combined company is likely to be a key player in the $45 billion musculoskeletal healthcare market. The hedge funds that we track at Insider Monkey boosted their investments in Zimmer Holdings slightly to $1.61 billion by the end of the first quarter compared to net investments of $1.54 billion three months earlier. Mario Gabelli‘s GAMCO Investors reported holding 288,317 shares of Zimmer as of June 30.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!